SHANGHAI, Dec. 7 WuXi PharmaTech (NYSE: WX), aleading pharmaceutical, biotechnology and medical device research anddevelopment outsourcing company with operations in China and the United States,announced today it has purchased a Labcyte POD(TM) 810 plate assemblerequipped with an Echo(R) 555 acoustic liquid handler for its work in high-throughput screening and secondary screening. WuXi PharmaTech joins thegrowing number of pharmaceutical companies worldwide that have incorporatedthe POD system into their compound management and HTS processes.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
"With this technology WuXi will remain the leader in pharmaceuticaloutsourcing-this demonstrates our continuous efforts to build bothcapabilities and capacity to help our partners to improve the success ofdiscovery and shorten development time," commented Dr Ge Li, Chairman andChief Executive Officer of WuXi PharmaTech.
"Acoustic liquid handling is clearly the method of choice in drugdiscovery," said Dr. Qiang Lu, Vice President of Discovery Biology of WuXiPharmaTech. "We are very pleased to incorporate the POD 810 into our systems.It will make our drug discovery efforts significantly more productive while itreduces cost through the elimination of disposable plastic tips. We know thatacoustic liquid handling will significantly improve the quality of the data wegenerate. We are looking forward to a continuing relationship with Labcyte."
The POD 810 plate assembler, a walk-away, out-of-the-box solution,transforms any Echo acoustic liquid handler into a Plates-On-Demand instrument.The POD system is controlled by its revolutionary Intellectual Scheduler withbuilt-in intelligence to automatically adjust workflow to maximizeproductivity.
"The POD platform is uniquely positioned to advance method standardizationacross global sites," said Mark Fischer-Colbrie, president and CEO of LabcyteInc. "It eliminates the unnecessary delays associated with customizedintegration."
"We are very pleased WuXi PharmaTech decided to acquire a Labcyte PODsystem," said Sanger Chang, General Manager of Tekon Biotech. "Our exclusiverelationship with Labcyte is further validation of our efforts to be theleading supplier of instrument systems for pharmaceutical research to theChinese market by providing the highest level of technical support andservice."For more information, please contact: WuXi PharmaTech (Cayman) Inc. Ronald Aldridge (for investors) Director of Investor Relations Tel: +1-201-585-2048 Email: [email protected]
Stephanie Liu (for the media) WuXi PharmaTech (Cayman) Inc. Tel: +86-21-5046-4362 Email: [email protected]
SOURCE WuXi PharmaTech (Cayman) Inc.